BIOTECHNOLOGY | Price | Marketcap | Equity | FV | SALES | PROFIT | Reserve | Debt&Lease | F-EPS | ||||||||||||||||
Biocon | 374 | 44567 | 600 | 5 | 7857 | 804 | 7287 | 3130 | 6 | ||||||||||||||||
S.CAGR | MARGIN | ICR | ROE | D2E | BV | PE | YIELD | Div% | |||||||||||||||||
15% | 8 | 10 | 10.2% | 40% | 66 | 61 | 1.6% | 5 | |||||||||||||||||
People | |||||||||||||||||||||||||
250 | 1999 | 32 | |||||||||||||||||||||||
Year (in cr) | Revenue | Profit | EPS | Interest | CA | Equity | Reserve | Margin | HighPrice | LowPrice | Bookvalue | HPE | LPE | Annual | |||||||||||
2003 | 283 | 44 | 4 | -2 | 2 | 124 | 16 | Year (amt in cr) | Revenue | EXP | FIN | PAT | EPS | MARGIN | ICR | ||||||||||
700.00 | 2004 | 549 | 139 | 14 | -2 | 50 | 491 | 25 | 2021 | 7106 | -6226 | -58 | 846 | 6.2 | 11.9 | 16.2 | |||||||||
2005 | 728 | 197 | 20 | -2 | 50 | 645 | 27 | 739 | 395 | 35 | 37 | 20 | 2020 | 6301 | -5315 | -65 | 871 | 6.4 | 13.8 | 16.2 | |||||
2006 | 793 | 174 | 17 | -2 | 50 | 753 | 22 | 538 | 392 | 42 | 32 | 23 | 13% | 17% | -11% | -3% | -2% | -14% | 0% | ||||||
2007 | 990 | 200 | 20 | -8 | 50 | 891 | 20 | 513 | 306 | 51 | 26 | 15 | |||||||||||||
2008 | 1090 | 225 | 22 | -10 | 50 | 1278 | 21 | 663 | 360 | 72 | 30 | 16 | Q1 | ||||||||||||
3500 | 2009 | 1673 | 117 | 6 | -5 | bonus 1:1 | 100 | 1274 | 7 | 276 | 87 | 71 | 50 | 16 | Year (amt in cr) | Revenue | EXP | FIN | PAT | EPS | MARGIN | ICR | |||
2010 | 2405 | 293 | 15 | -2 | 100 | 1466 | 12 | 305 | 141 | 88 | 20 | 9 | 2022 | 1761 | -1586 | -20 | 108 | 0.7 | 6.1 | 9.8 | |||||
2011 | 1858 | 340 | 17 | -2 | 100 | 1846 | 18 | 465 | 272 | 102 | 27 | 16 | 2021 | 1694 | -1460 | -13 | 168 | 1.3 | 9.9 | 19.0 | |||||
2012 | 2148 | 338 | 17 | -2 | 100 | 1996 | 16 | 390 | 229 | 114 | 23 | 13 | 4% | 9% | 54% | -36% | -44% | -38% | -49% | ||||||
2013 | 2538 | 509 | 26 | -1 | 100 | 2106 | 20 | 322 | 208 | 135 | 13 | 8 | |||||||||||||
2014 | 2933 | 413 | 16 | -1 | 100 | 2317 | 14 | 497 | 264 | 151 | 31 | 17 | H1 | ||||||||||||
7500 | 2015 | 3143 | 497 | 18 | -1 | 100 | 3170 | 16 | 554 | 402 | 164 | 31 | 22 | Year (amt in cr) | Revenue | EXP | FIN | PAT | EPS | MARGIN | ICR | ||||
2016 | 3485 | 550 | 20 | -10 | 100 | 3955 | 16 | 544 | 419 | 67 | 27 | 21 | 2022 | 3601 | -3205 | -42 | 268 | 1.9 | 7.4 | 10.4 | |||||
2017 | 3922 | 612 | 22 | -26 | 100 | 4737 | 16 | 1162 | 482 | 81 | 52 | 22 | 2021 | 3444 | -3003 | -19 | 363 | 2.7 | 10.5 | 24.2 | |||||
10000 | 2018 | 4335 | 432 | 6 | -62 | bonus 2:1 | 300 | 4880 | 10 | 658 | 296 | 86 | 104 | 47 | 5% | 7% | 121% | -26% | -30% | -29% | -57% | ||||
11000 | 2019 | 5659 | 905 | 8 | -71 | 300 | 6815 | 16 | 718 | 544 | 102 | 90 | 68 | ||||||||||||
12000 | 2020 | 6,301 | 846 | 6 | -65 | Bonus 1:1 | 600 | 6937 | 13 | 324 | 211 | 54 | 54 | 35 | 9M | ||||||||||
2021 | 7,143 | 846 | 6 | -58 | 600 | 7027 | 12 | 488 | 274 | 64 | 76 | 43 | Year (amt in cr) | Revenue | EXP | FIN | PAT | EPS | MARGIN | ICR | |||||
85 | 6637 | 3726 | 864 | 2022 | 5775 | -5056 | -57 | 488 | 3.4 | 8.5 | 13.6 | ||||||||||||||
Growth | 2021 | 5301 | -4646 | -24 | 550 | 4.1 | 10.4 | 28.3 | |||||||||||||||||
Year (in cr) | Revenue | Profit | EPS | Reserve | Margin | HighPrice | LowPrice | Bookvalue | HPE | LPE | Intrinsic | 8.9% | 9% | 138% | -11% | -16% | -19% | -52% | |||||||
Growth Long | 20% | 18% | 18% | (3 Bonsues) | 25% | 16 | 15% | 15% | 22% | 31 | 20 | 25 | |||||||||||||
Growth 10 Yr | 14% | 10% | 14% | 16 | 31 | 22 | 26 | ||||||||||||||||||
Growth 5 Yr | 15% | 9% | 16% | 12% | 15 | 65 | 39 | 52 | C Trend | ANNUAL | Q1 | H1 | 9M | F2022 | |||||||||||
Current Year | 9% | -11% | -16% | 8 | 26 | Sales | 13% | 4% | 5% | 9% | 10% | ||||||||||||||
Profits | -3% | -36% | -26% | -11% | -5% | ||||||||||||||||||||
Exp Growth | Revenue | PROFIT | MARGIN% | RESERVE |